Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All fluvoxamine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFluvoxamineFluvoxamine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Prospective cohort of fluvoxamine for early treatment of COVID-19

Seftel et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab050
Feb 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 72% Improvement Relative Risk Death/ICU 84% Hospitalization 94% Recovery 99% Fluvoxamine  Seftel et al.  EARLY TREATMENT Is early treatment with fluvoxamine beneficial for COVID-19? Prospective study of 125 patients in the USA Lower hospitalization (p=0.0026) and improved recovery (p<0.0001) c19early.org Seftel et al., Open Forum Infectious D.., Feb 2021 Favorsfluvoxamine Favorscontrol 0 0.5 1 1.5 2+
26th treatment shown to reduce risk in November 2021
 
*, now with p = 0.00014 from 21 studies, recognized in 3 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19early.org
Prospective quasi-randomized (patient choice) study with 125 outpatients, 77 treated with fluvoxamine, showing lower death/ICU admission (0 of 77 vs. 2 of 48), lower hospitalization (0 of 77 vs. 6 of 48), and faster recovery with treatment. Note that 12 treatment patients were added but are not reflected in the table in the paper (because the numbers had been previously published and the IRB did not allow updating the table).
risk of death, 72.3% lower, RR 0.28, p = 0.38, treatment 0 of 77 (0.0%), control 1 of 48 (2.1%), NNT 48, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of death/ICU, 83.9% lower, RR 0.16, p = 0.15, treatment 0 of 77 (0.0%), control 2 of 48 (4.2%), NNT 24, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of hospitalization, 94.0% lower, RR 0.06, p = 0.003, treatment 0 of 77 (0.0%), control 6 of 48 (12.5%), NNT 8.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of no recovery, 98.7% lower, RR 0.01, p < 0.001, treatment 0 of 77 (0.0%), control 29 of 48 (60.4%), NNT 1.7, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Seftel et al., 1 Feb 2021, prospective quasi-randomized (patient choice), USA, peer-reviewed, 2 authors.
This PaperFluvoxamineAll
Abstract: Open Forum Infectious Diseases Brief Report Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19 David Seftel1,2 and David R. Boulware3, 1 Golden Gate Fields Medical Clinic, Berkeley, California, USA, 2Enable Biosciences Inc, South San Francisco, California, USA, 3University of Minnesota Medical School, Minneapolis, Minnesota, USA We read with interest Lenze et al’s [1] double-blind randomized clinical trial testing fluvoxamine for early treatment of coronavirus disease 2019 (COVID-19). In this 152 person outpatient trial, fluvoxamine decreased clinical progression, defined as hypoxia (<92% oxygen saturation) coupled with either shortness of breath or hospitalization, from 8% (6 of 72) with observation alone to 0% (0 of 80) with fluvoxamine at up to 300 mg daily (P = .009) [1]. Although fluvoxamine is a selective serotonin reuptake inhibitor, fluvoxamine also activates sigma-1 receptors present intracellularly in the endoplasmic reticulum, thereby decreasing cytokine production [2]. We wish to share our recent real-world experience using fluvoxamine inspired by this recent trial. METHODS In November–December 2020, a mass outbreak of COVID-19 occurred in an occupational setting with congregate living at a horse racing track in California. We instituted 3 successive Received 21 December 2020; editorial decision 26 January 2021; accepted 27 January 2021. Correspondence: David Seftel, MD, MBA, Medical Director/Primary Care Clinician, Golden Gate Fields Medical Clinic, 1100 Eastshore Highway, Berkeley, CA 94710 (dseftel@ enablebiosciences.com). Open Forum Infectious Diseases®2021 © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/ by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com DOI: 10.1093/ofid/ofab050 Patient Consent Statement Patients consented for their medical treatment. As a quality improvement initiative, we assessed 14-day outcomes, analyzing the existing collected, deidentified data (Institutional Review Board exempt by the University of Minnesota). RESULTS Of 113 SARS-COV-2 antigen positive persons, approximately half were asymptomatic when initially tested. The median age was 42 years (interquartile range, 33 to 56), and 75% were men; 84% were Latino, and 14% were white. In total, 65 persons opted for fluvoxamine, and 48 opted for observation alone with no therapy. Demographics were generally similar among those choosing fluvoxamine versus observation, with the exception that more nonwhite persons opted for fluvoxamine (Table 1). Fewer patients opting for fluvoxamine were asymptomatic (38%) at time of initial diagnostic testing than those opting for observation (58%). Overall, 30% had 1 or more chronic medical comorbidities. Those opting for fluvoxamine had slightly more frequent diabetes (17% vs 8%) and slightly less treated hypertension (17% vs 35%) than those receiving observation. The incidence of subsequent hospitalization was 0% (0 of 65) with fluvoxamine and 12.5% (6 of 48) with observation (P = .005). Two persons required intensive care unit..
{ 'indexed': {'date-parts': [[2024, 4, 2]], 'date-time': '2024-04-02T05:19:45Z', 'timestamp': 1712035185717}, 'reference-count': 3, 'publisher': 'Oxford University Press (OUP)', 'issue': '2', 'license': [ { 'start': { 'date-parts': [[2021, 2, 1]], 'date-time': '2021-02-01T00:00:00Z', 'timestamp': 1612137600000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2021, 2, 1]]}, 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:p>We report a real-world experience using fluvoxamine for coronavirus ' 'disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 ' 'persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of ' 'hospitalization was 0% (0 of 65) with fluvoxamine and 12.5% (6 of 48) with observation alone. ' 'At 14 days, residual symptoms persisted in 0% (0 of 65) with fluvoxamine and 60% (29 of 48) ' 'with observation.</jats:p>', 'DOI': '10.1093/ofid/ofab050', 'type': 'journal-article', 'created': {'date-parts': [[2021, 2, 1]], 'date-time': '2021-02-01T05:16:18Z', 'timestamp': 1612156578000}, 'source': 'Crossref', 'is-referenced-by-count': 121, 'title': 'Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19', 'prefix': '10.1093', 'volume': '8', 'author': [ { 'given': 'David', 'family': 'Seftel', 'sequence': 'first', 'affiliation': [ {'name': 'Golden Gate Fields Medical Clinic, Berkeley, California, USA'}, {'name': 'Enable Biosciences Inc, South San Francisco, California, USA'}]}, { 'ORCID': 'http://orcid.org/0000-0002-4715-0060', 'authenticated-orcid': False, 'given': 'David R', 'family': 'Boulware', 'sequence': 'additional', 'affiliation': [ { 'name': 'University of Minnesota Medical School, Minneapolis, Minnesota, ' 'USA'}]}], 'member': '286', 'published-online': {'date-parts': [[2021, 2, 1]]}, 'reference': [ { 'key': '2021021717275727400_CIT0001', 'doi-asserted-by': 'crossref', 'first-page': '2292', 'DOI': '10.1001/jama.2020.22760', 'article-title': 'Fluvoxamine vs placebo and clinical deterioration in outpatients with ' 'symptomatic covid-19: a randomized clinical trial', 'volume': '324', 'author': 'Lenze', 'year': '2020', 'journal-title': 'JAMA'}, { 'key': '2021021717275727400_CIT0002', 'doi-asserted-by': 'crossref', 'first-page': 'eaau5266', 'DOI': '10.1126/scitranslmed.aau5266', 'article-title': 'Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in ' 'preclinical models of inflammation and sepsis', 'volume': '11', 'author': 'Rosen', 'year': '2019', 'journal-title': 'Sci Transl Med'}, { 'key': '2021021717275727400_CIT0003', 'doi-asserted-by': 'crossref', 'DOI': '10.1161/CIRCULATIONAHA.120.051718', 'article-title': 'Emulating randomized clinical trials with nonrandomized real-world ' 'evidence studies: first results from the RCT DUPLICATE Initiative', 'author': 'Franklin', 'year': '2020', 'journal-title': 'Circulation'}], 'container-title': 'Open Forum Infectious Diseases', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'http://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofab050/36152952/ofab050.pdf', 'content-type': 'application/pdf', 'content-version': 'am', 'intended-application': 'syndication'}, { 'URL': 'http://academic.oup.com/ofid/article-pdf/8/2/ofab050/36301401/ofab050.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'syndication'}, { 'URL': 'http://academic.oup.com/ofid/article-pdf/8/2/ofab050/36301401/ofab050.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 2, 17]], 'date-time': '2021-02-17T19:54:14Z', 'timestamp': 1613591654000}, 'score': 1, 'resource': {'primary': {'URL': 'https://academic.oup.com/ofid/article/doi/10.1093/ofid/ofab050/6124100'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 2, 1]]}, 'references-count': 3, 'journal-issue': {'issue': '2', 'published-print': {'date-parts': [[2021, 2, 1]]}}, 'URL': 'http://dx.doi.org/10.1093/ofid/ofab050', 'relation': {}, 'ISSN': ['2328-8957'], 'subject': ['Infectious Diseases', 'Oncology'], 'published-other': {'date-parts': [[2021, 2, 1]]}, 'published': {'date-parts': [[2021, 2, 1]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit